--- canonical_name: Fasting-Mimicking Diet alternate_names: FMD, ProLon, Prolonged Fasting-Mimicking Diet, Periodic Fasting-Mimicking Diet canonical_topic: Fasting-Mimicking Diet for Health & Longevity short_topic_lc: fasting_mimicking_diet creation_date: 2026-0712-0308 creator_ai_fullname: Opus 4.8 --- # Fasting-Mimicking Diet for Health & Longevity
Evidence Review created on 07/12/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 4.8 **Also known as:** FMD, ProLon, Prolonged Fasting-Mimicking Diet, Periodic Fasting-Mimicking Diet ## Motivation The fasting-mimicking diet (FMD) is a short, plant-based, low-calorie eating pattern designed to nudge the body into a fasting-like state while a person still eats small meals. It was created to capture the benefits of multi-day water fasting without its difficulty, and is typically followed for five days at a time, then repeated every one to several months. Much of the interest comes from a simple idea: briefly lowering the intake of food, sugar, and protein may switch cells out of "growth mode" and into a "repair and cleanup mode" that is linked to healthier aging. The approach grew out of laboratory work on how nutrients control aging, and was later packaged both as a commercial five-day kit and as do-it-yourself versions. A widely cited human study reported that a few monthly cycles lowered body weight, blood sugar, and several markers tied to long-term disease risk, which helped move the diet from the laboratory into wider use among health- and longevity-focused adults. This review examines what the evidence shows about the fasting-mimicking diet for general health and longevity — its proposed benefits, its risks, how it is typically practiced, and where the science is still unsettled. **[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)** ## Recommended Reading This section collects high-level, expert-driven content that introduces the fasting-mimicking diet and the reasoning behind it. * [Valter Longo, Ph.D. on the Fasting-Mimicking Diet & Fasting for Longevity, Cancer & Multiple Sclerosis](https://www.foundmyfitness.com/episodes/valter-longo) - Rhonda Patrick A long-form interview with Valter Longo, who developed the diet, covering its origins and proposed effects on longevity, cancer, and autoimmune conditions. It is valuable for hearing the lead researcher explain the reasoning and human data in accessible terms, though Longo holds a financial interest in the commercial version of the diet. * [Fasting: foundations, mechanisms, outcomes and application](https://peterattiamd.com/topic-guide/fasting/) - Peter Attia A curated topic guide that places the fasting-mimicking diet within the broader landscape of fasting strategies and weighs how strong the underlying evidence actually is. Attia is notably cautious, making this a useful counterbalance to more enthusiastic coverage. * [Effects of Fasting & Time Restricted Eating on Fat Loss & Health](https://www.hubermanlab.com/episode/effects-of-fasting-and-time-restricted-eating-on-fat-loss-and-health) - Andrew Huberman A detailed walkthrough of how fasting affects fat loss, metabolism, and the longevity pathways that underlie the fasting-mimicking approach. It explains the physiology of the fasted state in practical, non-technical language. * [Rebooting the System: The Benefits of a Fasting Mimicking Diet](https://kresserinstitute.com/rebooting-system-benefits-fasting-mimicking-diet/) - Chris Kresser A practitioner-oriented article that contrasts the fasting-mimicking diet with ordinary intermittent fasting and reviews the animal and human evidence condition by condition. It is helpful for understanding who might respond best and the practical distinctions between approaches. * [Avoiding Holiday Weight Gain with Nutrient-Supported Intermittent Calorie Restriction](https://www.lifeextension.com/magazine/2018/12/prevent-holiday-weight-gain) - Kirk Stokel A consumer-facing article describing the branded five-day version of the diet and a trial reporting reduced weight and vascular risk markers. It illustrates how the intervention is marketed and applied outside the laboratory. ## Grokipedia * [Fasting-mimicking diet](https://grokipedia.com/page/Fasting-mimicking_diet) Grokipedia hosts a dedicated encyclopedia entry on the fasting-mimicking diet that summarizes its definition, mechanisms, and research base. It offers a broad reference overview with links to primary studies for readers who want a neutral starting point. ## Examine No dedicated Examine.com article for the fasting-mimicking diet was found. Examine.com's coverage in this area is limited to broader fasting and intermittent-fasting material rather than a standalone page for this specific dietary program. ## ConsumerLab No dedicated ConsumerLab.com article or product review for the fasting-mimicking diet was found. ConsumerLab focuses on independent testing of supplements and packaged products, and its search returns only tangential material on intermittent fasting rather than a review of this dietary program. ## Systematic Reviews This section summarizes systematic reviews and meta-analyses evaluating the fasting-mimicking diet and closely related fasting regimens across cardiometabolic, diabetic, oncologic, hormonal, and microbiome outcomes. * [Impact of Fasting Mimicking Diet (FMD) on cardiovascular risk factors: a systematic review and meta-analysis of randomized control trials.](https://pubmed.ncbi.nlm.nih.gov/40287774/) - Mohammadzadeh et al., 2025 Pooled randomized trials to assess how repeated fasting-mimicking cycles affect blood pressure, cholesterol, blood sugar, and body weight. It is the most directly relevant synthesis of controlled human data on cardiovascular risk markers, and it highlights that effects vary by outcome. * [Exploring the Impact of Fasting and Fasting-Mimicking Diets on Type 2 Diabetes Management in Adults: A Systematic Review.](https://pubmed.ncbi.nlm.nih.gov/39469384/) - Rivera Regalado et al., 2024 Reviews controlled and observational studies on how fasting and fasting-mimicking approaches influence blood-sugar control and medication needs in adults with type 2 diabetes. It is useful for gauging the diet's metabolic relevance in a high-risk group. * [Fasting-mimicking diets as a strategy to reprogram tumor metabolism: a systematic review.](https://pubmed.ncbi.nlm.nih.gov/41677881/) - Pereira et al., 2026 Synthesizes preclinical and clinical evidence on how the fasting-mimicking diet alters tumor metabolism and interacts with cancer therapy. It clarifies which oncology claims rest on animal work versus human data. * [The effectiveness of fasting regimens on serum levels of some major weight regulating hormones: a GRADE-assessed systematic review and meta-analysis in randomized controlled trial.](https://pubmed.ncbi.nlm.nih.gov/40176106/) - Tavakoli et al., 2025 A certainty-rated meta-analysis of randomized trials examining how fasting regimens, including the fasting-mimicking diet, change appetite- and weight-regulating hormones such as leptin. It helps explain the mechanisms behind observed weight changes. * [Gut microbiome changes and cancer immunotherapy outcomes associated with dietary interventions: a systematic review of preclinical and clinical evidence.](https://pubmed.ncbi.nlm.nih.gov/40629403/) - Somodi et al., 2025 Evaluates how dietary interventions, including fasting-mimicking approaches, reshape the gut microbiome and may influence immune-related outcomes. It situates the diet within the emerging diet–microbiome–immunity picture. ## Mechanism of Action The fasting-mimicking diet works by lowering the intake of calories, sugar, and especially protein for several consecutive days, which quiets the body's main nutrient-sensing pathways and triggers a coordinated fasting-like state. * **Lower IGF-1 and insulin signaling:** When protein and calories drop, levels of insulin and of insulin-like growth factor 1 (IGF-1) — a hormone that signals cells to grow and divide — fall. Lower IGF-1 shifts cells away from growth and toward maintenance and repair. * **Reduced mTOR and PKA activity:** Two growth-promoting pathways, mTOR (mechanistic target of rapamycin, a master switch that drives cell growth when nutrients are plentiful) and PKA (protein kinase A, part of a sugar-sensing pathway), are turned down, which is thought to activate cellular stress-resistance and cleanup programs. * **Increased AMPK and autophagy:** As energy runs low, AMPK (AMP-activated protein kinase, a cellular energy sensor) rises and promotes autophagy — the process by which cells break down and recycle their own damaged parts. * **Ketone production and fat burning:** With little incoming sugar, the body shifts to burning fat and making ketones (an alternative fuel derived from fat), and fasting-induced hormones such as FGF21 (fibroblast growth factor 21, a hormone that helps regulate energy use during fasting) rise. * **Regeneration on refeeding:** Animal work suggests that returning to normal eating after each cycle triggers stem-cell-based renewal of tissues, so the fasting-then-refeeding cycle — not fasting alone — is proposed to drive regeneration. * **Competing mechanistic explanations:** One view holds that the diet's benefits come from a distinct, periodic "deep fasting" switch that ordinary calorie counting cannot reproduce. A competing view argues that most measured improvements track with the calorie deficit and weight loss themselves, meaning any equivalent reduction in calories might produce similar short-term effects. Current human data cannot yet fully separate these explanations. * **Not a pharmacological compound:** Because the fasting-mimicking diet is a dietary regimen rather than a drug, standard drug properties — half-life, receptor selectivity, tissue distribution, and enzymatic metabolism — do not apply. ## Historical Context & Evolution * **Original intended use:** The fasting-mimicking diet grew out of laboratory research in the 2000s and 2010s on how nutrients control aging and stress resistance, first in simple organisms and then in mice. An early goal was to protect healthy cells during cancer chemotherapy through "differential stress resistance," while leaving tumor cells without that protection. * **Path to health optimization:** Building on findings that periodic fasting improved metabolic and aging markers, researchers designed a food-based program meant to reproduce fasting's effects without complete starvation. A widely cited human study in 2017 reported improvements in weight, blood sugar, and disease-risk markers, which propelled interest in the diet for general health and longevity. * **Findings, not just reception:** Animal studies reported extended healthspan, immune-cell renewal, and tissue regeneration, while early human trials showed reductions in weight and cardiometabolic markers. These findings are described here on their own terms rather than only through later commentary. * **Commercialization and conflict of interest:** The diet was commercialized as ProLon through L-Nutra, a company co-founded by Valter Longo, who developed the diet; he has stated that his proceeds are directed to a nonprofit foundation. Because much of the supporting research comes from his group, this financial interest is relevant when weighing the evidence. * **Evolving scientific opinion:** Early enthusiasm has been tempered by questions about how much of the benefit is unique to the diet versus attributable to calorie restriction and weight loss, and by the short duration of most trials. Rather than treating any position as settled, the field continues to test whether periodic fasting cycles offer advantages beyond simply eating less, with new randomized trials emerging on both sides. ## Expected Benefits The benefits below are framed for risk-aware, proactive adults seeking to optimize long-term health, not for the average person. Where a benefit depends on starting from an unhealthy baseline, this is noted, since much of this audience already sits near optimal ranges. ### High 🟩 🟩 🟩 #### Body Weight, Waist Circumference & Body Fat Reduction The fasting-mimicking diet reliably reduces body weight and preferentially trims abdominal (visceral) fat while largely preserving lean muscle, an effect attributed to its low-calorie, low-protein makeup that pushes the body toward burning fat. The evidence includes randomized human trials of three monthly cycles and a meta-analysis of controlled trials. Some of the loss rebounds if normal eating resumes without other changes, so benefits accumulate with repeated cycles rather than a single round. **Magnitude:** Roughly 2–4 kg (about 4–9 lb) of body-weight loss and about 1–2 cm of waist reduction after three monthly 5-day cycles, with fat loss favored over lean mass. #### Improved Fasting Glucose & Insulin Sensitivity The diet lowers fasting blood sugar and improves how the body responds to insulin, driven by reduced calorie and sugar intake and a shift toward fat burning. A human randomized controlled trial (RCT) — the most rigorous study design, in which participants are randomly assigned to the diet or a comparison group — reported reductions that were larger in people whose starting values were elevated. For those already near optimal levels, the change is smaller. **Magnitude:** Fasting glucose reductions on the order of 5–12 mg/dL across cycles, greatest in people with higher baseline values. ### Medium 🟩 🟩 #### Reduced IGF-1 & Improved Biological-Age Markers Repeated cycles lower IGF-1 and shift a panel of blood and liver markers toward a profile associated with younger biological age, consistent with the diet's core nutrient-sensing effects. Evidence includes a controlled human study estimating reduced biological-age markers after three cycles, supported by mechanistic reasoning. Because IGF-1 has both harmful and protective roles, chronically very low levels may not be uniformly beneficial. **Magnitude:** IGF-1 reductions of roughly 10–25% during and shortly after cycles; one analysis estimated about 2.5 years of lower biological-age markers after three cycles. #### Improved Blood Lipids & Blood Pressure ⚠️ Conflicted Some trials report reductions in cholesterol, triglycerides, and blood pressure, but a meta-analysis of randomized trials found that effects on several cardiovascular markers were inconsistent or not statistically significant. The evidence is conflicted because pooled controlled trials diverge — likely reflecting differences in participants' baseline risk, cycle number, and trial size. Benefits appear largest in people who begin with elevated readings. **Magnitude:** Systolic blood pressure reductions of about 3–7 mmHg and triglyceride reductions of about 10–20 mg/dL in positive trials; other trials show no significant change. #### Reduced Systemic Inflammation The diet can lower C-reactive protein (CRP), a general marker of inflammation, mainly in people whose baseline level is elevated. The proposed mechanism combines fat loss with the fasting state's dampening of inflammatory signaling. Human trial data support this, though effects in already low-inflammation individuals are minimal. **Magnitude:** High-sensitivity CRP (hs-CRP) reductions of roughly 20–40% in participants with elevated baseline, with little change when baseline is already low. #### Improved Glycemic Control in Type 2 Diabetes In adults with type 2 diabetes, structured monthly cycles integrated into routine care improved HbA1c (average blood sugar over about three months) and reduced the need for glucose-lowering medication. Evidence comes from a 12-month randomized primary-care trial. This benefit is most relevant to audience members who already have impaired blood sugar rather than those with normal metabolism. **Magnitude:** Modest HbA1c reductions and de-prescribing of glucose-lowering medication in a meaningful share of participants over 12 months, versus usual care. ### Low 🟩 #### Reduced Chemotherapy Toxicity & Enhanced Anti-Cancer Efficacy In cancer patients — not the primary healthy audience — fasting-mimicking cycles around chemotherapy were generally safe and, in some randomized and early-phase trials, were linked to better tumor response and possibly fewer side effects. The proposed mechanism is that normal cells enter a protected, low-growth state during fasting while tumor cells do not. The evidence is early and based largely on small trials. **Magnitude:** In a randomized breast-cancer chemotherapy trial, higher rates of favorable tumor response with the diet versus a normal diet; effect sizes remain uncertain given small samples. #### Autoimmune & Inflammatory Bowel Symptom Modulation Small human studies and early randomized trials in inflammatory bowel disease (IBD) and multiple sclerosis (MS) suggest that fasting-mimicking cycles can reduce symptoms and inflammatory markers, supported by animal models showing gut and nerve regeneration. The mechanism is thought to involve resetting overactive immune activity during the fasting-and-refeeding cycle. Findings are preliminary and based on small samples. **Magnitude:** Symptom and inflammatory-marker improvements reported in small controlled and pilot studies; magnitudes are not yet firmly established. ### Speculative 🟨 #### Lifespan Extension & Delayed Aging Mouse studies found that periodic fasting-mimicking cycles extended healthspan and, in some measures, lifespan, alongside improvements in aging markers. There is no human lifespan data, so this benefit rests on animal experiments and mechanistic reasoning about nutrient-sensing pathways. Whether the effect translates to human longevity is unknown. #### Immune-System Regeneration & Stem-Cell Renewal In mice, fasting cycles appeared to clear damaged immune cells and stimulate stem-cell-based renewal of the blood and immune system on refeeding. Human evidence is limited to indirect markers, so the claim is currently mechanistic and animal-based rather than demonstrated in people. #### Neuroprotection & Cognitive Preservation Mouse models of Alzheimer's disease showed reduced brain inflammation and better cognition with fasting-mimicking cycles. Human trials are only now underway, so the potential for protecting the aging brain remains speculative and grounded in animal and mechanistic data. ## Benefit-Modifying Factors * **Genetic factors:** People carrying variants linked to insulin resistance or a strong family history of type 2 diabetes may see larger metabolic gains, while carriers of the APOE ε4 gene variant (a version of the APOE gene that raises the risk of Alzheimer's disease) are a specific focus of ongoing brain-aging studies. * **Baseline biomarker levels:** Those starting with higher glucose, weight, blood pressure, or inflammation tend to benefit most; individuals already near optimal ranges — common in this audience — should expect smaller measurable changes. * **Sex-based differences:** Women may respond differently to prolonged energy restriction because of effects on reproductive and stress hormones, and some evidence suggests they may need gentler or less frequent cycling to obtain benefits without side effects. * **Pre-existing health conditions:** Metabolic conditions such as obesity, prediabetes, and type 2 diabetes tend to amplify measurable benefits, whereas lean, metabolically healthy individuals have less room to improve. * **Age-related considerations:** Middle-aged and older adults with early metabolic decline may benefit more, but those at the older end of the target range must balance benefits against a greater risk of losing muscle, which can offset metabolic gains. ## Potential Risks & Side Effects Risks are framed for the target audience of proactive, health-focused adults; most side effects are short-lived, but a subset of individuals face meaningfully higher risk and are flagged below. ### High 🟥 🟥 🟥 #### Hunger, Fatigue & Weakness Reduced calorie intake during the 5-day cycle commonly causes hunger, tiredness, and a sense of low energy, particularly on the middle days. These effects are driven directly by the energy deficit and the shift to fat-based fuel, and they resolve quickly once normal eating resumes. They are the most frequently reported experiences in human trials. **Magnitude:** Reported by a majority of participants during cycles as mild-to-moderate and transient, typically peaking on days 2–3. #### Headache & Lightheadedness Headaches and lightheadedness are common during cycles, linked to lower blood sugar, fluid and salt loss, and mild dehydration. They are usually mild and respond to hydration and electrolytes. Because they overlap with everyday triggers, they are easy to under- or over-attribute to the diet. **Magnitude:** Commonly reported (roughly one-quarter to one-half of participants in trials), generally mild and resolving within the cycle. ### Medium 🟥 🟥 #### Hypoglycemia in Those on Glucose-Lowering Medication In people taking insulin or other blood-sugar-lowering drugs, the diet's glucose-lowering effect can stack with medication to cause hypoglycemia (dangerously low blood sugar), with shakiness, confusion, or fainting. The mechanism is additive glucose lowering. This is a predictable, potentially serious risk that requires medical supervision and dose adjustment. **Magnitude:** Risk concentrated in medicated diabetics; can be clinically significant without proactive dose reduction, but largely avoidable with supervision. #### Orthostatic Hypotension & Dizziness Lower food and salt intake, combined with fluid loss, can reduce blood pressure enough to cause dizziness on standing (orthostatic hypotension, a drop in blood pressure when moving upright). The effect is amplified in people already taking blood-pressure medication. It is usually manageable with fluids and salt but can raise fall risk in older adults. **Magnitude:** Modest average blood-pressure reductions during cycles; symptomatic dizziness is occasional and more likely in medicated or older individuals. ### Low 🟥 #### Lean Mass Loss with Repeated Cycling Frequent cycles without adequate protein refeeding can gradually erode muscle, especially in older adults or those doing little resistance training. The mechanism is repeated energy and protein restriction outpacing muscle rebuilding between cycles. Careful refeeding and appropriate cycle spacing largely prevent it. **Magnitude:** Small per-cycle lean-mass changes that can accumulate with frequent cycling; generally preventable with protein-forward refeeding. #### Gastrointestinal Discomfort Some people experience nausea, bloating, or diarrhea during the cycle or when reintroducing food, related to low intake, high fiber from plant foods, and changes in gut activity. Symptoms are typically mild and self-limited. Gradual refeeding reduces their likelihood. **Magnitude:** Occasional and mild in trials; more likely during abrupt refeeding. #### Sleep Disturbance & Irritability Hunger and lower evening blood sugar can fragment sleep and worsen mood or focus during cycles. The mechanism involves the stress response to energy restriction. These effects are transient and improve between cycles. **Magnitude:** Variable and individual; commonly described as mild disruption limited to the fasting days. ### Speculative 🟨 #### Triggering or Worsening of Disordered Eating In people with a history of eating disorders, the structured restriction and refeeding pattern could reinforce unhealthy relationships with food. Evidence is largely from clinical caution and isolated reports rather than controlled studies, but the concern is serious enough to warrant screening. #### Gallstone Formation from Weight Cycling Rapid or repeated weight loss can raise the risk of gallstones, a known association with aggressive calorie restriction. Whether the intermittent nature of the fasting-mimicking diet meaningfully increases this risk is not established and rests on indirect evidence. #### Sarcopenia Risk in Frail Older Adults In frail or underweight older adults, repeated restriction could accelerate age-related muscle loss (sarcopenia). This risk is inferred from general principles of aging and undernutrition rather than direct trials of the diet in this group. ## Risk-Modifying Factors * **Genetic factors:** Variants affecting glucose handling or blood-pressure regulation can influence how strongly the diet lowers these values and therefore the likelihood of hypoglycemia or low blood pressure during cycles. * **Baseline biomarker levels:** Low starting body weight, low blood sugar, or low blood pressure raises the chance of side effects such as dizziness and excessive weight loss, whereas robust baselines are more forgiving. * **Sex-based differences:** Women, particularly those of reproductive age, may be more sensitive to prolonged restriction, with potential effects on menstrual regularity and stress hormones; pregnancy and breastfeeding are contraindications. * **Pre-existing health conditions:** Diabetes treated with insulin, cardiovascular disease, a history of eating disorders, and being underweight all increase risk and call for medical oversight or avoidance. * **Age-related considerations:** Older adults, especially those over about 70 or with low muscle mass, face greater risks of muscle loss, falls from low blood pressure, and slow recovery, so cycles should be less frequent and more closely supervised. ## Key Interactions & Contraindications * **Glucose-lowering medications (insulin; sulfonylureas such as glipizide and glyburide):** Caution to absolute need for supervision — the diet's blood-sugar-lowering effect adds to these drugs and can cause hypoglycemia. Mitigation: medical supervision with proactive dose reduction before and during each cycle, plus frequent glucose checks. * **Blood-pressure medications (ACE inhibitors — a class of blood-pressure drugs that relax blood vessels, such as lisinopril; diuretics such as hydrochlorothiazide):** Caution — added to fluid loss and low intake, these can cause symptomatic low blood pressure and fainting. Mitigation: monitor blood pressure and have a clinician consider lowering doses during cycles. * **Over-the-counter medications (NSAIDs — over-the-counter pain relievers such as ibuprofen; aspirin):** Caution — taking these on the near-empty stomach of a fasting day increases gastrointestinal (GI, relating to the stomach and intestines) irritation and bleeding risk. Mitigation: take with the diet's meals or avoid unnecessary use during cycles. * **Medications that require food (e.g., metformin, some antibiotics):** Monitor — low food intake can worsen stomach upset or change tolerability. Mitigation: take with the scheduled meals of the diet, or separate timing as advised. * **Supplement interactions (iron; high-dose fat-soluble vitamins A, D, E, K):** Monitor — these are often poorly tolerated on minimal food, and fat-soluble vitamins absorb less well on very low-fat days. Mitigation: time them with the fattier meals or pause during the cycle. * **Additive blood-sugar and blood-pressure supplements (berberine, cinnamon, magnesium, potassium):** Monitor — these can add to the diet's glucose- and pressure-lowering effects. Mitigation: watch for lightheadedness or low readings and adjust doses as needed. * **Other metabolic interventions (prolonged water-only fasting, ketogenic diets, SGLT2 inhibitors — a class of diabetes drugs that flush sugar out through the urine, such as empagliflozin):** Caution — stacking strong metabolic interventions can amplify hypoglycemia, dehydration, or a dangerous acid buildup (ketoacidosis), particularly SGLT2 inhibitors combined with very low carbohydrate intake. Mitigation: avoid combining without clinician guidance. * **Populations who should avoid the diet or use it only under medical supervision:** pregnant or breastfeeding women; people who are underweight (body mass index, or BMI, under 18.5) or frail; adults over about 70 with low muscle mass; anyone with a history of eating disorders; people with type 1 diabetes; those with advanced liver, kidney, or heart disease; and anyone on insulin without supervision. ## Risk Mitigation Strategies * **Medical supervision for medicated individuals:** For anyone on glucose- or blood-pressure-lowering drugs, arrange clinician oversight with medication dose reduction or holding before each cycle and glucose or blood-pressure monitoring, which directly prevents hypoglycemia and fainting. * **Adequate hydration and electrolytes:** Aim for roughly 2–3 liters of fluid per day with added sodium and potassium during cycles to prevent the headaches, dizziness, and orthostatic hypotension caused by fluid and salt loss. * **Protein-forward refeeding:** Reintroduce food gradually over about one day, adding protein after the cycle, to prevent lean-mass loss and reduce gastrointestinal upset from abrupt refeeding. * **Appropriate cycle frequency:** Limit cycles to at most monthly for active goals and every 3–6 months for maintenance, which prevents the excessive weight loss, muscle loss, and nutrient gaps that come from over-frequent restriction. * **Screening for eating-disorder history and low BMI:** Avoid the diet in anyone with disordered-eating history or a BMI under 18.5, which prevents triggering unhealthy eating patterns and unsafe weight loss. * **Reduced exercise intensity during cycles:** Scale back to light activity during the 5 days to prevent the excessive fatigue, hypoglycemia, and injury risk that come from hard training on very low energy intake. ## Therapeutic Protocol * **Standard 5-day cycle:** Leading practitioners describe roughly 1,100 calories on day 1 and about 700–800 calories on days 2–5, plant-based, higher in healthy fats and low in protein and sugar, repeated monthly to quarterly depending on goals — the structure popularized by Valter Longo's group and the commercial ProLon kit. * **Competing approaches:** The branded five-day kit, do-it-yourself plant-based versions built to the same calorie and macronutrient targets, and longer supervised water-only fasting are all in use; none is clearly superior for general health, and each trades convenience, cost, and intensity differently. * **Who popularized each approach:** The fasting-mimicking diet was developed in Valter Longo's laboratory and commercialized as ProLon; cautious integrative clinicians such as Peter Attia discuss it as one option among several fasting strategies. * **Best time of day:** Calories are typically spread across the day rather than taken at one time; no strong evidence favors a specific schedule, though eating earlier in the day may reduce sleep disruption. * **Compound half-life and single-versus-split dosing (not applicable):** Because this is a dietary regimen rather than a supplement or medication, there is no compound half-life, and single-versus-split-dose considerations do not apply beyond spreading meals across the day. * **Genetic considerations:** People with insulin-resistance-related variants or a family history of diabetes may see larger metabolic gains, and APOE ε4 carriers are a specific focus of ongoing brain-aging trials that may inform future protocol choices. * **Sex-based differences:** Some evidence suggests women may benefit from gentler or less frequent cycling to avoid effects on reproductive and stress hormones. * **Age-related considerations:** Adults at the older end of the target range should use less frequent cycles with careful protein refeeding to protect muscle. * **Baseline biomarkers:** Those with higher starting glucose, weight, or inflammation typically respond most; near-optimal individuals should set modest expectations. * **Pre-existing conditions:** People with diabetes, cardiovascular disease, or complex medication regimens need individualized, supervised protocols rather than a generic schedule. ## Discontinuation & Cycling * **Periodic, not continuous:** The diet is inherently cyclical — a 5-day cycle followed by weeks of normal eating — and is not meant to be followed continuously or lifelong. * **Withdrawal effects:** There is no physiological dependence or withdrawal; the main pitfall on stopping a cycle is rebound overeating. * **Refeeding transition:** Rather than a medical taper, a gentle one-day reintroduction of normal foods — starting light, then adding protein — is advised to avoid digestive upset. * **Cycling for maintenance:** Cycling is the intended design: monthly cycles for active goals, then every 3–6 months for maintenance; measurable benefits fade if cycles stop and other habits do not change. * **Long-term pattern:** Most protocols use repeated low-frequency cycles indefinitely rather than setting a fixed end date. ## Sourcing and Quality * **Commercial kit versus do-it-yourself:** ProLon (made by L-Nutra) provides pre-portioned 5-day boxes, while do-it-yourself versions replicate the calorie and macronutrient targets using whole plant foods; both can achieve the fasting-like state if the targets are met. * **What to look for:** For kits, choose a reputable manufacturer with transparent nutrition labeling; for do-it-yourself, hit accurate calorie and low-protein targets using nutrient-dense whole foods such as vegetables, nuts, olives, and soups. * **Purity and formulation:** Favor minimally processed ingredients and avoid added sugars or excess protein, which would break the fasting-like metabolic state the diet depends on. * **Reputable sources and disclosure:** ProLon from L-Nutra is the main clinically studied commercial product; buyers should be aware that Valter Longo, who developed the diet, has a financial interest in L-Nutra, with stated proceeds directed to a nonprofit foundation. ## Practical Considerations * **Time to effect:** Some markers such as blood sugar and weight shift within a single 5-day cycle, but durable benefits require repeated cycles over several months. * **Common pitfalls:** Eating too much protein or sugar during the cycle (which breaks the fasting state), overeating immediately afterward, running cycles too frequently, and neglecting hydration and electrolytes are the most common mistakes. * **Regulatory status:** The commercial version is marketed as a "medical food" or dietary program rather than an approved drug; the U.S. Food and Drug Administration (FDA) has not approved it as a treatment for any disease, and do-it-yourself use is unregulated. * **Cost and accessibility:** Commercial 5-day kits are relatively expensive — roughly US$150 per cycle — which can be a barrier, whereas do-it-yourself versions cost far less but require careful planning to match the targets. ## Interaction with Foundational Habits * **Sleep:** Indirect and often negative during cycles — hunger and lower evening blood sugar can fragment sleep; front-loading calories earlier in the day and maintaining evening electrolytes may reduce disruption. Between cycles, sleep typically returns to baseline. * **Nutrition:** Direct — the diet is itself a nutrition protocol that is plant-based and low in protein during the cycle, with protein reintroduced afterward; the practical priority is ensuring overall nutrient adequacy across the whole month, not just the fasting days. * **Exercise:** Direct and blunting — energy is limited during cycles, so intense or heavy resistance training should be scaled back to light activity to avoid excessive fatigue and muscle loss, with normal training resumed between cycles to preserve lean mass. * **Stress management:** Indirect — fasting is a mild stressor that can transiently raise the stress hormone cortisol; pairing cycles with a lighter schedule, relaxation practices, and good sleep improves tolerance and recovery. ## Monitoring Protocol & Defining Success Before beginning, a baseline assessment establishes starting values so that changes can be judged objectively; this is best done in the week before the first cycle, when the person is eating normally. Ongoing monitoring is then repeated after the first cycle, again at about 3 months (roughly three cycles), and thereafter every 6–12 months for those who continue periodic cycling. | Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes | | --- | --- | --- | --- | | Fasting glucose | 70–85 mg/dL | Tracks the diet's core metabolic effect | Requires an 8–12 h fast; conventional "normal" extends to <100 mg/dL | | HbA1c | <5.4% | Reflects longer-term blood-sugar control | Lags changes by ~3 months; conventional cutoff is <5.7% | | Fasting insulin | 2–6 µIU/mL | Sensitive early marker of insulin resistance | Pair with glucose to calculate HOMA-IR (a simple index of insulin resistance) | | IGF-1 | Mid-to-lower end of age-adjusted range | The hormone the diet most directly lowers | Interpret by age and sex; very low long-term levels may not be desirable | | hs-CRP | <1.0 mg/L | Marker of systemic inflammation | High-sensitivity assay; avoid testing during acute illness or injury | | Triglycerides | <80 mg/dL | Fat metabolism and cardiometabolic risk | Fasting sample; conventional cutoff is <150 mg/dL | | LDL cholesterol | Context-dependent, generally <100 mg/dL | Low-density lipoprotein, the "bad" cholesterol tied to heart-disease risk | May transiently rise while fat is being mobilized during a cycle | | Blood pressure | <120/80 mmHg | Safety and cardiovascular benefit tracking | Check seated and on standing if dizziness occurs | | Electrolytes (sodium, potassium) | Mid-normal range | Safety during low food intake | Especially useful if dizziness or palpitations occur | | eGFR | >90 mL/min/1.73 m² | Kidney function and safety | eGFR is the estimated glomerular filtration rate, a measure of kidney function; relevant when protein intake shifts | Qualitative markers complement the labs and often shift sooner: * **Energy levels** during and between cycles * **Mental clarity and focus** * **Hunger and satiety** patterns after refeeding * **Sleep quality** * **Mood and stress resilience** * **Physical performance** and recovery between cycles ## Emerging Research Research is framed for proactive, health-focused adults, spanning trials that could strengthen the case for the diet and questions that could weaken it. * **Longevity and biological-aging biomarkers (Varapodio follow-up):** A follow-up study testing whether repeated fasting-mimicking and longevity-diet cycles improve body fat, cardiovascular risk factors, and biomarkers of aging in overweight adults — [NCT07255300](https://clinicaltrials.gov/study/NCT07255300); sponsor Fondazione Valter Longo; about 135 participants; primary endpoint body-fat percentage. It could strengthen the case by measuring aging markers directly in otherwise healthy adults. * **Brain aging in APOE ε4 carriers (NIBBLE):** A six-month fasting-mimicking study evaluating safety and effects on brain blood flow in carriers of the higher-risk APOE ε4 gene variant — [NCT06682767](https://clinicaltrials.gov/study/NCT06682767); sponsor Cedars-Sinai Medical Center; about 40 participants; primary focus on safety and cerebral blood flow. * **Multiple sclerosis quality of life:** A trial testing whether fasting-mimicking cycles improve health-related quality of life in people with multiple sclerosis — [NCT06515782](https://clinicaltrials.gov/study/NCT06515782); sponsor University of Southern California; about 50 participants. * **Prostate cancer control and metabolism:** A Phase 2 trial evaluating a fasting-mimicking approach for prostate cancer control alongside metabolic outcomes — [NCT05832086](https://clinicaltrials.gov/study/NCT05832086); about 138 participants; Phase 2. * **Future direction — biological-age effects:** Whether monthly cycles measurably lower biological age in healthy adults remains open; a 2024 analysis suggested reduced biological-age markers ([Brandhorst et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38378685/)), but larger confirmatory trials are needed. * **Future direction — diabetes and medication reduction:** Whether the diet can safely reduce diabetes medication over the long term is being examined after a 12-month primary-care trial reported reduced medication needs ([van den Burg et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38546821/)). * **Open question — beyond calorie restriction:** A central unresolved question, which could weaken the case, is whether the fasting-mimicking diet outperforms simple calorie restriction of equal size; several trials are designed to compare the two directly. ## Conclusion The fasting-mimicking diet is a short, repeatable eating pattern that briefly lowers calories, sugar, and protein to push the body into a fasting-like state while still allowing small meals. For adults focused on long-term health, the most consistent human evidence points to modest reductions in body weight and belly fat, along with improvements in blood sugar and several markers tied to aging and heart health — effects that are largest in people who start with higher-than-ideal levels and smaller for those already near optimal. Signals for lowering long-term disease risk, protecting the brain, calming an overactive immune system, and supporting cancer care are promising but rest largely on animal work and small or early human studies. The main downsides are short-lived — hunger, fatigue, headaches, and lightheadedness during the fasting days — though people on blood-sugar or blood-pressure medication, those who are underweight or frail, and anyone with a history of disordered eating face greater risk and warrant closer oversight. Much of the supporting research comes from the group that developed and commercialized the diet, a conflict of interest worth keeping in mind. A recurring open question is how much of the benefit is unique to the diet versus simply eating less and losing weight. Overall, the evidence base is young and mostly short-term, with the firmest support for near-term metabolic gains and far less certainty about lasting effects on lifespan. **[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**